Gold standard monitoring of HCC in patients with cirrhosis is cost-effective

Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis. A new analysis indicates that following screening guidelines for HCC in cirrhotic patients is lifesaving and cost-effective compared with 'real life' monitoring.

Compared with 'real life' monitoring, following the guidelines for screening—which recommends biannual ultrasound—increased life expectancy by an average of 5 months and was cost-effective at $1754 per additional life year gained with French costs and at $32,415 per additional life year gained with US costs.

"The large difference between French and US costs was explained by the 4- to 10-fold difference in unit costs for surveillance—clinic visits, tests—and for first-line curative treatments," said Dr. Isabelle Durand-Zaleski, co-author of the Hepatology study.


Explore further

New anticancer drugs up costs and life expectancy considerably

More information: Benjamin Cadier et al, Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States, Hepatology (2017). DOI: 10.1002/hep.28961
Provided by Wiley
Citation: Gold standard monitoring of HCC in patients with cirrhosis is cost-effective (2017, February 8) retrieved 17 February 2019 from https://medicalxpress.com/news/2017-02-gold-standard-hcc-patients-cirrhosis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more